Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients

Trial Profile

Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Aspirin; Warfarin
  • Indications Cerebral infarction
  • Focus Therapeutic Use
  • Acronyms DECISIVE
  • Most Recent Events

    • 08 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top